Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 1

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT07226349 · tracked via the Priya Life Science USA tracker
Phase
Phase 1
Started
2025-12-11
Last updated
2026-09-28

Condition(s) studied

Advanced Solid Tumor

Investigational drug(s) / intervention(s)

BG-75098BGB-43395 →Fulvestrant →

BG-75098: Administered orally.

BGB-43395: Administered orally.

Fulvestrant: Administered by intramuscular injection.

Study summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants must have measurable disease as assessed by RECIST v1.1. * Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have adequate organ function. * Dose Escalation Part A: Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors potentially associated with cyclin-dependent kinase 2 (CDK2) dependency. Participants should have received prior treatment with available standard-of-care (SOC) systemic therapies for advanced/metastatic disease, or for whom standard therapy is not available or not tolerated. * Dose Escalation Part B: Patients with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors who have received ≥ 1 prior line of systemic therapy in the metastatic setting. * Dose Expansion Cohort 1: Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable CDK4/6 inhibitor-progressed solid tumors. * Dose Expansion Cohort 2: Participants with advanced solid tumors. Participants with primary platinum refractory disease are not eligible. Participants should have received ≥ 1 line of platinum-containing chemotherapy and ≤ 4 prior therapeutic regimens in the advanced/metastatic setting. Exclusion Criteria: * For all cohorts: Prior therapy selectively targeting CDK2 inhibition or degradation. * For combination cohorts: Prior therapy selectively targeting CDK4. Prior CDK4/6 inhibitor standard of care therapy is permitted and required in local regions where it is approved and available. * Participants with active leptomeningeal disease or uncontrolled, untreated brain metastasis. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcome measure(s)

  • Phase 1a: Number of Participants with Adverse Events (AEs) — From first dose to 30 days after last dose, up to approximately 12 months
    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including physical examination findings, electrocardiogram results, laboratory values, and AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria.
  • Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-75098 — Up to approximately 2 years
    MTD is determined based on a target for dose-limiting toxicities. MAD is defined as the maximum administered dose, and it is used when MTD is not reached.
  • Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-75098 as Monotherapy and in Combination with BGB-43395 and Fulvestrant — Up to approximately 2 years
    The RDFE(s) will be determined from safety, tolerability, pharmacokinetic, pharmacodynamic biomarker(s), preliminary antitumor activity, and any other relevant data that are obtained from the dose escalation phase.
  • Phase 1b: Objective Response Rate (ORR) as Assessed by the Investigator — Up to approximately 2 years
    ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR), as assessed by the investigator using RECIST v1.1.

Trial sites (23)

FacilityCityRegionStatus
University of Alabama At Birmingham Hospital Birmingham Alabama Recruiting
City of Hope National Medical Center Duarte California Recruiting
Yale Cancer Center New Haven Connecticut Recruiting
Sidney Kimmel Comprehensive Cancer At Johns Hopkins Baltimore Maryland Recruiting
Massachusetts General Hospital Boston Massachusetts Recruiting
The University of Texas Md Anderson Cancer Center Houston Texas Recruiting
Next Oncology Houston Houston Texas Recruiting
Medical College of Wisconsin Milwaukee Wisconsin Recruiting
Blacktown Cancer and Haematology Centre Blacktown New South Wales Recruiting
Genesiscare St Leonards St Leonards New South Wales Recruiting
Icon Cancer Centre Wesley Auchenflower Queensland Recruiting
Cabrini Hospital Malvern Malvern Victoria Recruiting
Peter Maccallum Cancer Centre Melbourne Victoria Recruiting
One Clinical Research Nedlands Western Australia Recruiting
Cancer Hospital Chinese Academy of Medical Sciences Beijing Beijing Municipality Recruiting
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) Guangzhou Guangdong Recruiting
Harbin Medical University Cancer Hospital Harbin Heilongjiang Recruiting
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch Wuhan Hubei Recruiting
Jiangsu Province Hospital Longjiang Branch Nanjing Jiangsu Recruiting
Qilu Hospital of Shandong University Jinan Shandong Recruiting
Weifang Peoples Hospital Weifang Shandong Recruiting
Rigshospitalet Copenhagen Denmark Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07226349 on ClinicalTrials.gov ↗ ← All trials in the USA